ac

ACADIA Pharmaceuticals

ACAD
NASDAQ
$21.83

Does ACADIA Pharmaceuticals have high-quality management?

CEO Catherine Owen Adams, appointed in September 2024, brings deep commercial experience from BMS and J&J and has begun executing on DAYBUE STIX and NUPLAZID field expansion while communicating clear 2026 milestones.

Tenure is still short, so long‑term capital deployment skill remains to be proven in this seat, but early execution and guidance reaffirmation are encouraging. Board composition includes experienced operators and life sciences investors.

Read the full report on ACADIA Pharmaceuticals and explore the other sections

Overview
Overview of ACADIA Pharmaceuticals
Moat
Does ACADIA Pharmaceuticals have a strong competitive moat?
Pricing Power
Does ACADIA Pharmaceuticals have pricing power in its industry?
Predictability
How predictable is ACADIA Pharmaceuticals's business?
Financial Strength
Is ACADIA Pharmaceuticals financially strong?
Capital Allocation
How effective is ACADIA Pharmaceuticals's capital allocation strategy?
Management
Does ACADIA Pharmaceuticals have high-quality management?
Fair Value
What is the fair value of ACADIA Pharmaceuticals stock?